CANOPY_1170x120_9-21-20

Fred Wilkinson

Impax to introduce Adderall XR generic

Impax to introduce Adderall XR generic

HAYWARD, Calif. — Impax Laboratories Inc. has received Food and Drug Administration approval for dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules, mixed amphetamine product used for the treatment of attention deficit hyperactivity disorder (ADHD). Impax said Wednesday that its mixed amphetamine product, a CII controlled substance, comes in dosages of

Impax to release Emverm chewable tablets

Impax to release Emverm chewable tablets

HAYWARD, Calif. — Impax Laboratories Inc. has received Food and Drug Administration approval for its supplemental new drug application for Emverm 100-mg chewable tablets, a medication for parasitic worms. Ampex said Friday that Emverm (mebendazole) is indicated for the treatment of pinworm (Enterobius vermicularis), whipworm (Trichuris trichiura), common roundworm (Ascaris lumbricoides), common hookworm (Ancylostoma duodenale)

Impax cleared to market Intuniv generic

Impax cleared to market Intuniv generic

HAYWARD, Calif. — Impax Laboratories Inc. has received approval from the Food and Drug Administration for guanfacine extended-release tablets, a treatment for attention deficit hyperactivity disorder (ADHD). Impax said late Wednesday that its guanfacine ER product, a generic version of Intuniv from Shire, comes in strengths of 1 mg, 2 mg, 3 mg and 4

Impax’s Zomig Nasal Spray OK’d as pediatric migraine treatment

Impax’s Zomig Nasal Spray OK’d as pediatric migraine treatment

HAYWARD, Calif. — Impax Specialty Pharma’s Zomig Nasal Spray has been approved by the Food and Drug Administration for use in children ages 12 and older for the acute treatment of migraine. Parent company Impax Laboratories Inc. said Tuesday that the product  is the first nasal-delivered prescription medicine approved for the treatment of acute migraine